UniSuper Management Pty Ltd Has $2.19 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

UniSuper Management Pty Ltd grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.9% in the 4th quarter, HoldingsChannel reports. The fund owned 30,428 shares of the medical equipment provider’s stock after purchasing an additional 5,671 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Hologic were worth $2,194,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the company. Brooklyn Investment Group lifted its holdings in Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 145 shares during the last quarter. Smartleaf Asset Management LLC increased its position in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares during the period. Trivant Custom Portfolio Group LLC boosted its position in shares of Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after acquiring an additional 169 shares during the period. UMB Bank n.a. boosted its position in shares of Hologic by 4.1% in the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock valued at $343,000 after acquiring an additional 188 shares during the period. Finally, Capital Investment Counsel Inc grew its stake in shares of Hologic by 3.6% in the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock valued at $413,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Down 1.6 %

Shares of NASDAQ:HOLX opened at $61.32 on Monday. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The company has a market capitalization of $13.76 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a fifty day moving average of $65.24 and a 200-day moving average of $73.24.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HOLX. William Blair reissued an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Morgan Stanley cut their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Evercore ISI cut their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research report on Thursday, February 6th. Finally, Jefferies Financial Group assumed coverage on Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.